Vir Biotechnology CEO Marianne De Backer at JPM20 (Jeff Rumans)
Vir’s GSK-allied flu prevention antibody fails PhII, sinking shares and late-stage hope
Vir Biotechnology’s influenza antibody has failed a critical Phase II clinical trial, which could spell bad news for its partner GSK, who has the option …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.